Form 4: Corcept Therapeutics Chief Business Officer Increases Stake Through Share Purchase and Restricted Stock Awards

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc., has increased his beneficial ownership in the company through a share purchase plan and the grant of restricted stock awards.

Summary

• Gary Charles Robb, Chief Business Officer of Corcept Therapeutics Inc. (CORT), acquired 997 shares of common stock on June 2, 2025, at a price of $71.68 per share, as part of a purchase plan under the 2024 Incentive Award Plan.
• Additionally, Mr. Robb was granted 997 shares underlying unvested restricted stock awards on June 2, 2025, with a price of $0, also under the Purchase Plan, which will vest on the one-year anniversary of the grant date.
• On June 3, 2025, 651 shares of common stock were disposed of at $71.68 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Mr. Robb's direct beneficial ownership stands at 16,549 shares of common stock.
• His direct holdings include 503 unvested restricted stock awards granted on September 3, 2024, 290 unvested restricted stock awards granted on December 2, 2024, and 292 unvested restricted stock awards granted on March 3, 2025, all vesting 100% on their respective one-year anniversaries.
• Mr. Robb also holds an indirect beneficial ownership of 23,142 shares (11,571 shares in each of two separate custodial accounts for a child under the Uniform Transfers to Minors Act, for which he is custodian).

Sentiment

Score: 7

Explanation: The sentiment is positive due to the Chief Business Officer's increased beneficial ownership through a direct share purchase and the grant of restricted stock awards, signaling confidence and alignment with shareholder interests. The share disposition was for tax purposes, which is a neutral event.

Positives

• The Chief Business Officer's acquisition of 997 shares through a purchase plan at market price ($71.68) demonstrates a direct investment and confidence in the company's future.
• The grant of 997 unvested restricted stock awards further aligns management's interests with shareholders, incentivizing long-term performance.
• The increase in overall beneficial ownership (direct and indirect) by a key executive signals strong insider commitment.

Negatives

• The disposition of 651 shares was solely for tax withholding purposes, which is a common occurrence upon vesting of equity awards and not indicative of a negative outlook.

Future Outlook

The document indicates future vesting of restricted stock awards on their one-year anniversaries, contingent on the reporting person satisfying certain requirements and remaining the beneficial owner of the Purchase Plan Shares.

Industry Context

This Form 4 filing details routine insider transactions related to executive compensation and a stock purchase plan, which are common practices across the biotechnology and pharmaceutical industries to align executive incentives with shareholder value. It does not provide broader industry trends or competitive analysis.

Related Party Transactions

• The acquisition of shares under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan and Purchase Plan represents a transaction between the reporting person and the issuer.
• Indirect beneficial ownership is held through custodial accounts for a child, where the reporting person is the custodian, which constitutes a related party holding.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive sign of management's commitment and belief in the company's future performance.
• Employees, particularly those with equity compensation, may see this as a reinforcement of the company's compensation structure and long-term incentive alignment.

Next Steps

• The unvested restricted stock awards granted on June 2, 2025, are expected to vest on their one-year anniversary, provided the reporting person remains the beneficial owner of the Purchase Plan Shares.
• Other unvested restricted stock awards granted on September 3, 2024, December 2, 2024, and March 3, 2025, are expected to vest on their respective one-year anniversaries.

Key Dates

Recommendation

Keywords

Corcept Therapeutics, CORT, SEC Form 4, Insider Trading, Stock Purchase Plan, Restricted Stock Awards, Executive Compensation, Beneficial Ownership, Chief Business Officer, Equity Compensation